Agomelatine in Depressive Disorders: Its Novel Mechanisms of Action
Disruptions in sleep and sleep–wake cycle regulation have been identified as one of the main causes for the pathophysiology of depressive disorders. The search has been on for the identification of an ideal antidepressant that could improve both sleep disturbances and depressive symptomatology...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Psychiatric Publishing
2012
|
| Subjects: | |
| Online Access: | http://eprints.usm.my/44437/1/2012_JNCN_-_Agomelatine_in_Depressive_Disorders.pdf |
| _version_ | 1797011185130799104 |
|---|---|
| author | Srinivasan, Venkataramanujan Zakaria, Rahimah Othman, Zahiruddin Lauterbach, Edward C. Acuña-Castroviejo, Darío |
| author_facet | Srinivasan, Venkataramanujan Zakaria, Rahimah Othman, Zahiruddin Lauterbach, Edward C. Acuña-Castroviejo, Darío |
| author_sort | Srinivasan, Venkataramanujan |
| collection | USM |
| description | Disruptions in sleep and sleep–wake cycle
regulation have been identified as one of the main
causes for the pathophysiology of depressive
disorders. The search has been on for the
identification of an ideal antidepressant that could
improve both sleep disturbances and depressive
symptomatology. Melatonin, the major hormone of
the pineal gland, has been shown to improve sleep
and is involved in the regulation of the sleep–wake
cycle. Identification of high concentrations of MT1
and MT2 melatonergic receptors in the
suprachiasmatic nucleus of the anterior
hypothalamus, the structure concerned with
regulation of circadian rhythms and sleep–wake
cycles, has led to the development of melatonergic
agonists with greater potency and longer durations
of action. Agomelatine is one such melatonergic
agonist that acts specifically on MT1/MT2
melatonergic receptors and at the same time exhibits
5-HT2C antagonism, a property that is utilized by
current antidepressants that are in clinical use.
Agomelatine has been shown to be effective in
a number of animal models of depression. |
| first_indexed | 2024-03-06T15:30:38Z |
| format | Article |
| id | usm.eprints-44437 |
| institution | Universiti Sains Malaysia |
| language | English |
| last_indexed | 2024-03-06T15:30:38Z |
| publishDate | 2012 |
| publisher | American Psychiatric Publishing |
| record_format | dspace |
| spelling | usm.eprints-444372019-05-30T01:32:27Z http://eprints.usm.my/44437/ Agomelatine in Depressive Disorders: Its Novel Mechanisms of Action Srinivasan, Venkataramanujan Zakaria, Rahimah Othman, Zahiruddin Lauterbach, Edward C. Acuña-Castroviejo, Darío RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry Disruptions in sleep and sleep–wake cycle regulation have been identified as one of the main causes for the pathophysiology of depressive disorders. The search has been on for the identification of an ideal antidepressant that could improve both sleep disturbances and depressive symptomatology. Melatonin, the major hormone of the pineal gland, has been shown to improve sleep and is involved in the regulation of the sleep–wake cycle. Identification of high concentrations of MT1 and MT2 melatonergic receptors in the suprachiasmatic nucleus of the anterior hypothalamus, the structure concerned with regulation of circadian rhythms and sleep–wake cycles, has led to the development of melatonergic agonists with greater potency and longer durations of action. Agomelatine is one such melatonergic agonist that acts specifically on MT1/MT2 melatonergic receptors and at the same time exhibits 5-HT2C antagonism, a property that is utilized by current antidepressants that are in clinical use. Agomelatine has been shown to be effective in a number of animal models of depression. American Psychiatric Publishing 2012 Article PeerReviewed application/pdf en http://eprints.usm.my/44437/1/2012_JNCN_-_Agomelatine_in_Depressive_Disorders.pdf Srinivasan, Venkataramanujan and Zakaria, Rahimah and Othman, Zahiruddin and Lauterbach, Edward C. and Acuña-Castroviejo, Darío (2012) Agomelatine in Depressive Disorders: Its Novel Mechanisms of Action. Journal of Neuropsychiatry and Clinical Neurosciences, 24 (3). pp. 290-308. ISSN 0895-0172 https://neuro.psychiatryonline.org/doi/10.1176/appi.neuropsych.11090216 |
| spellingShingle | RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry Srinivasan, Venkataramanujan Zakaria, Rahimah Othman, Zahiruddin Lauterbach, Edward C. Acuña-Castroviejo, Darío Agomelatine in Depressive Disorders: Its Novel Mechanisms of Action |
| title | Agomelatine in Depressive Disorders: Its Novel Mechanisms of Action |
| title_full | Agomelatine in Depressive Disorders: Its Novel Mechanisms of Action |
| title_fullStr | Agomelatine in Depressive Disorders: Its Novel Mechanisms of Action |
| title_full_unstemmed | Agomelatine in Depressive Disorders: Its Novel Mechanisms of Action |
| title_short | Agomelatine in Depressive Disorders: Its Novel Mechanisms of Action |
| title_sort | agomelatine in depressive disorders its novel mechanisms of action |
| topic | RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry |
| url | http://eprints.usm.my/44437/1/2012_JNCN_-_Agomelatine_in_Depressive_Disorders.pdf |
| work_keys_str_mv | AT srinivasanvenkataramanujan agomelatineindepressivedisordersitsnovelmechanismsofaction AT zakariarahimah agomelatineindepressivedisordersitsnovelmechanismsofaction AT othmanzahiruddin agomelatineindepressivedisordersitsnovelmechanismsofaction AT lauterbachedwardc agomelatineindepressivedisordersitsnovelmechanismsofaction AT acunacastroviejodario agomelatineindepressivedisordersitsnovelmechanismsofaction |